Announced details
Pharmaceutical manufacturing sites; maintenance and troubleshooting for tablet inspection equipment
Not disclosed. The company describes qualitatively the reduction of production line stoppage risk, faster troubleshooting, and contribution to stable operation.
Ikegami Tsushinki Co., Ltd. delivered the TIE-10000 to Sawai Pharmaceutical Co., Ltd.'s Kyushu Plant and added the remote maintenance function to the equipment. Capital and personnel relationships are not disclosed.
Pharmaceutical manufacturer with a Kyushu Plant. Other information, including locations, representative, capital, and year established, is not disclosed.
Sawai Pharmaceutical Co., Ltd., Kyushu Plant. Detailed location is not disclosed.
The company has indicated a policy of using this initiative to expand its service business, but the specific amount or percentage impact on financial results is not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | TIE-10000, TIE-10000 remote maintenance function |
| Counterparty | Sawai Pharmaceutical Co., Ltd. |
| Counterparty overview | Pharmaceutical manufacturer with a Kyushu Plant. Other information, including locations, representative, capital, and year established, is not disclosed. |
| Relationship with the Company | Ikegami Tsushinki Co., Ltd. delivered the TIE-10000 to Sawai Pharmaceutical Co., Ltd.'s Kyushu Plant and added the remote maintenance function to the equipment. Capital and personnel relationships are not disclosed. |
| Launch date | Already implemented as of the announcement on 6 April 2026. The specific implementation date is not disclosed. |
| Applicable area | Pharmaceutical manufacturing sites; maintenance and troubleshooting for tablet inspection equipment |
| Location | Sawai Pharmaceutical Co., Ltd., Kyushu Plant. Detailed location is not disclosed. |
| Quantitative Effects | Not disclosed. The company describes qualitatively the reduction of production line stoppage risk, faster troubleshooting, and contribution to stable operation. |
| Impact on Business Performance | The company has indicated a policy of using this initiative to expand its service business, but the specific amount or percentage impact on financial results is not disclosed. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To resolve delays in information sharing and discrepancies in understanding caused by inadequate communications environments, which had been longstanding issues at pharmaceutical manufacturing sites, thereby reducing the risk of production line stoppages and ensuring stable operation.